AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25947167
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) - 10 sessions, 30 minutes each, 2-10 Hz, intensity by tolerance, twice per week
Trial: 23357545
Drug: Essential amino
RxNorm normalized name: Essential amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential amino acids (EAA) 6.7 g
Trial: 12061999
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment including lipid lowering drugs (52%), beta-blockers (50%), antiplatelet drugs (87%), ACE inhibitors (32%), nitrates (52%), calcium antagonists (31%), oral anticoagulants (8%)
Trial: 9691642
Drug: Intracervical application
RxNorm normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracervical application of 0.5 mg dinoprostone gel
Trial: 195328
Drug: Regimen I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen I: 3 months of INH + RMP (2/7) in hospital, followed by 6 months of INH + SM (2/7) or INH + EMB (2/7) in ambulatory treatment.
Trial: 195328
Drug: Regimen II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen II: 3 months of INH + SM + EMB (2/7) in hospital, followed by 6 months of INH + SM (2/7) or INH + EMB (2/7) in ambulatory treatment.
Trial: 31691018
Drug: p-synephrine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p-synephrine (3 mg kg-1)
Trial: 28291262
Drug: Bumetanide (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide (0.5, 1.0 or 2.0 mg twice daily)
Trial: 21078615
Drug: ARC1779 (83
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARC1779 (83 and 250 nmol/L)
Trial: 21078615
Drug: abciximab (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: abciximab (100 nmol/L)
Trial: 19156121
Drug: Memantine (M)
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Memantine (M) 5 mg daily for 1 week, then 10 mg daily for 1 week, then 15 mg daily for 1 week, then 20 mg daily from the 4th week
Trial: 16820073
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream for 4 weeks
Trial: 16820073
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream for 8 weeks
Trial: 16820073
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream for 12 weeks
Trial: 16820073
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream for 16 weeks
Trial: 12669393
Drug: Wide-field hemibody
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wide-field hemibody irradiation or systemic administration of radioisotopes
Trial: 11783142
Drug: Baoyuan Qiangshen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baoyuan Qiangshen Capsule No. II (BYQS) combined with Lotensin
Trial: 2196622
Drug: Nefazodone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone (100 mg to 200 mg daily)
Trial: 28880941
Drug: One-day educational
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-day educational program for health workers in intravenous treatment
Trial: 28880941
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics in nursing homes
Trial: 28880941
Drug: Intravenous fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluids in nursing homes
Trial: 19640363
Drug: Market capsule
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Market capsule formulation
Trial: 19640363
Drug: Market suspension
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Market suspension
Trial: 19640363
Drug: Clinical trial
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical trial suspension
Trial: 19640363
Drug: All formulations
RxNorm normalized name: Novel Influenza-H1N1-09, all formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All formulations (market suspension, clinical trial suspension, market capsule)
Trial: 17635595
Drug: Naratriptan 1
RxNorm normalized name: naratriptan 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naratriptan 1 mg twice daily for 6 days
Trial: 12200522
Drug: Bronchial asthma
RxNorm normalized name: CVS Bronchial Asthma Relief 12.5mg-200mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchial asthma patients after 3 weeks of treatment with oral glucocorticoids (n=20)
Trial: 9866667
Drug: Mupirocin cream
RxNorm normalized name: Mupirocin Cream
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mupirocin cream applied topically 3 times daily
Trial: 9866667
Drug: Oral cephalexin
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cephalexin given 4 times daily
Trial: 7622767
Drug: 0.05 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/m2 IFN-gamma treatment
Trial: 32041
Drug: Metoprolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (10 mg i.v.)
Trial: 32041
Drug: Bunitrolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bunitrolol (10 mg i.v.)
Trial: 32041
Drug: Oxprenolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol (10 mg i.v.)
Trial: 21508090
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplementation (400 μg/d)
Trial: 25725940
Drug: Oral immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunotherapy (OIT) with dehydrated egg white
Trial: 21859559
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PHY906 with irinotecan, 5‐fluorouracil (5‐FU), and leucovorin (LV)
Trial: 17874238
Drug: Metformin (1,700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1,700 mg daily)
Trial: 8694355
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 ml 0.9% saline)
Trial: 6755389
Drug: m‐Amsa (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m‐Amsa (200 mg/m2 x 5 days) with Ara‐C (200 mg/m2 x 5 days)
Trial: 6755389
Drug: m‐Amsa (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m‐Amsa (200 mg/m2 x 5 days)
Trial: 6755389
Drug: m‐Amsa (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m‐Amsa (120 mg/m2 x 7 days) with Ara‐C (200 mg/m2 x 5 days)
Trial: 6755389
Drug: m‐Amsa (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m‐Amsa (high doses)
Trial: 6755389
Drug: m‐Amsa (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m‐Amsa (high doses) with Ara‐C (high doses)
Trial: 6755389
Drug: Previous high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous high doses of anthracyclins
Trial: 28095813
Drug: Vocational rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vocational rehabilitation augmented with cognitive behaviour therapy (CBT)
Trial: 18635693
Drug: MDMA (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (1.6 mg/kg b.wt.)
Trial: 18635693
Drug: Pindolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (20 mg)
Trial: 15326236
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg/day for 28 days, followed by 10 mg/day as per clinician's judgment)
Trial: 11561261
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I (air-buffered injections, n = 25)
Trial: 11561261
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (conventional injections, n = 19)
Trial: 31736381
Drug: Tadalafil 20
RxNorm normalized name: tadalafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 20 mg oral daily
Trial: 31736381
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (no drug)
Trial: 27285965
Drug: Fp MDPI
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fp MDPI 25 µg
Trial: 27285965
Drug: Fp MDPI
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fp MDPI 50 µg
Trial: 27285965
Drug: Fp MDPI
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fp MDPI 100 µg
Trial: 27285965
Drug: Fp DPI
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fp DPI 100 µg
Trial: 23507227
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (800 μg) and vitamin B(12) (1000 μg)
Trial: 19338157
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus Xuefu Zhuyu Capsule (XFZYC)
Trial: 18043171
Drug: Topical indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical indomethacin eyedrops
Trial: 15138424
Drug: TCRFTA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCRFTA treatment (3 tongue treatments)
Trial: 15138424
Drug: TCRFTA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCRFTA treatment (2 additional tongue and palate treatments)
Trial: 10223915
Drug: Gatifloxacin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin alone (treatment A)
Trial: 10223915
Drug: Gatifloxacin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin alone (treatment D)
Trial: 10223915
Drug: Aluminum magnesium
RxNorm normalized name: Aluminum magnesium silicate
DrugBank: Aluminum acetate (DB14518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aluminum magnesium hydroxide 2 h before gatifloxacin (treatment B)
Trial: 10223915
Drug: Aluminum magnesium
RxNorm normalized name: Aluminum magnesium silicate
DrugBank: Aluminum acetate (DB14518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aluminum magnesium hydroxide concomitant with gatifloxacin (treatment C)
Trial: 10223915
Drug: Aluminum magnesium
RxNorm normalized name: Aluminum magnesium silicate
DrugBank: Aluminum acetate (DB14518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aluminum magnesium hydroxide 2 h after gatifloxacin (treatment E)
Trial: 10223915
Drug: Aluminum magnesium
RxNorm normalized name: Aluminum magnesium silicate
DrugBank: Aluminum acetate (DB14518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aluminum magnesium hydroxide 4 h after gatifloxacin (treatment F)
Trial: 7879932
Drug: Propofol 1.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1.10 mg/kg
Trial: 7879932
Drug: Ketamine 0.39
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.39 mg/kg
Trial: 7879932
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Propofol 0.63 mg/kg and Ketamine 0.21 mg/kg
Trial: 7879932
Drug: Propofol 1.85
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1.85 mg/kg
Trial: 7879932
Drug: Ketamine 0.66
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.66 mg/kg
Trial: 7879932
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Propofol 1.05 mg/kg and Ketamine 0.35 mg/kg
Trial: 7879932
Drug: Propofol 1.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1.61 mg/kg
Trial: 7879932
Drug: Ketamine greater
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine greater than 0.85 mg/kg
Trial: 7879932
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Propofol 1.50 mg/kg and Ketamine 0.50 mg/kg
Trial: 7879932
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Propofol and Ketamine
Trial: 7879932
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (Propofol, Ketamine, Combination)
Trial: 30601452
Drug: TX‐001HR (17β‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TX‐001HR (17β‐estradiol and progesterone combined in a single, oral, softgel capsule)
Trial: 21934569
Drug: Patient-delivered partner
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-delivered partner therapy (PDPT)
Trial: 19728711
Drug: Porridge with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porridge with 4 g of beta-glucan
Trial: 19728711
Drug: Granola with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granola with 4 g of beta-glucan
Trial: 19728711
Drug: Bread with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bread with 4 g of beta-glucan
Trial: 19728711
Drug: Pasta with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasta with 4 g of beta-glucan
Trial: 17911186
Drug: Argatroban therapy
RxNorm normalized name: Argatroban
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Argatroban therapy (N = 390; mean dose of 1.9 microg/kg/min for a mean 6 days)
Trial: 17911186
Drug: Historical control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical control therapy (N = 98)
Trial: 17911186
Drug: Argatroban therapy
RxNorm normalized name: Argatroban
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Argatroban therapy
Trial: 15819461
Drug: Quinine capsule
RxNorm normalized name: quinine Oral Capsule
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinine capsule
Trial: 15819461
Drug: Quinine tablet
RxNorm normalized name: quinine Oral Tablet
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinine tablet
Trial: 15819461
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of quinine
Trial: 9190868
Drug: Alprazolam 2
RxNorm normalized name: alprazolam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 2 mg/2 min i.v.
Trial: 1539815
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (0.2 mg/h) + epidural bupivacaine (10 mg/h)
Trial: 1539815
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (0.2 mg/h) alone
Trial: 4002781
Drug: Muzolimine (M)
RxNorm normalized name: Coenzyme M
DrugBank: Muzolimine (DB13801)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muzolimine (M) 240 mg oral dose during dialysis (A)
Trial: 4002781
Drug: Muzolimine (M)
RxNorm normalized name: Coenzyme M
DrugBank: Muzolimine (DB13801)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muzolimine (M) 240 mg oral dose after dialysis (B)
Trial: 30656180
Drug: Omaveloxolone 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omaveloxolone 160 mg/day
Trial: 30656180
Drug: Omaveloxolone 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omaveloxolone 160 mg/day in patients without pes cavus
Trial: 22402059
Drug: α‐lipoic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α‐lipoic acid (ALA) 600 mg/day
Trial: 20002340
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (20 minutes hands-on massage)
Trial: 17383643
Drug: Adept (4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adept (4% icodextrin solution)
Trial: 17383643
Drug: LRS (lactated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LRS (lactated Ringer's solution)
Trial: 11384630
Drug: CEE 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.3 mg/d plus MPA 1.5 mg/d
Trial: 11384630
Drug: CEE 0.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.45 mg/d plus MPA 1.5 mg/d
Trial: 11384630
Drug: CEE 0.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.45 mg/d plus MPA 2.5 mg/d
Trial: 11384630
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 mg/d plus MPA 2.5 mg/d
Trial: 23842013
Drug: Adjunctive agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive agents in placebo-controlled clinical trials
Trial: 12483404
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available amino acid solution (AA)
Trial: 12483404
Drug: Lysine 25
RxNorm normalized name: lysine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine 25 g
Trial: 12483404
Drug: Lysine 50
RxNorm normalized name: lysine 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine 50 g
Trial: 12483404
Drug: Lysine 75
RxNorm normalized name: aztreonam lysine 75 mg/mL INHALATION VIAL, NEBULIZER (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine 75 g
Trial: 12483404
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 25 g of lysine plus 25 g of arginine (LysArg)
Trial: 12483404
Drug: Fluid infusion
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid infusion alone (500, 1,000 or 2,000 ml of saline/glucose)
Trial: 12483404
Drug: No amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No amino acid infusion (controls)
Trial: 12483404
Drug: Lysine 75
RxNorm normalized name: aztreonam lysine 75 mg/mL INHALATION VIAL, NEBULIZER (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine 75 g (Lys75)
Trial: 9561594
Drug: Intramuscular artemether
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular artemether (loading dose of 160 mg, followed by 80 mg daily for another 6 doses)
Trial: 9561594
Drug: Quinine (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (intravenous infusion of loading dose of 20 mg/kg, followed by 10 mg/kg q 8 hourly for 7 days)
Trial: 3886401
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg single dose
Trial: 3886401
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg three times daily for one week
Trial: 3886401
Drug: Hydrochlorothiazide 50
RxNorm normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 50 mg daily for one week
Trial: 22787177
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin Glargine (GL)
Trial: 9532991
Drug: Transcervical amnioinfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcervical amnioinfusion of 800 mL saline at 15 mL per minute, followed by a maintenance infusion at 3 mL per minute
Trial: 9532991
Drug: Transcervical amnioinfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcervical amnioinfusion of 800 mL saline
Trial: 2676650
Drug: Enterococcus SF68
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enterococcus SF68 (one capsule twice daily for prevention; three times daily for treatment)
Trial: 2676650
Drug: Enterococcus SF68
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enterococcus SF68 (three times daily for treatment)
Trial: 8383415
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg iron daily
Trial: 29067756
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil (OM)–based single-pill dual-combination therapy (OM+amlodipine/azelnidipine or hydrochlorothiazide)
Trial: 19730391
Drug: Olmesartan monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan monotherapy
Trial: 27318919
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (DEX) infusion at 0.5 μg/kg before induction and 0.2 μg/(kg×h) intraoperatively
Trial: 19583073
Drug: Rectal acetaminophen
RxNorm normalized name: acetaminophen Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal acetaminophen 40 mg/kg
Trial: 12228083
Drug: Internet-based curriculum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based curriculum on herbs and dietary supplements (10 weeks, 20 case-based modules)